Planetary Health
Mental Health
AMR
Caregiver
Pharmacy
COVID-19
Global Health Education
Ebola
Natural Hazards
Conflict
Zika
TB
Cholera
Leprosy
HIV
Polio
Rapid Response
Refugee
Disability
Specific Hazards
Social Ethics
MEDBOX is an innovative online library aimed at improving the quality of healthcare in humanitarian action, worldwide.
MEDBOX is an independent internet platform supported by international agencies and scientific institutions active in humanitarian assistance, development and health work worldwide. MEDBOX collates the increasing number of professional guidelines, textbooks and practical documents on health action available online today and brings these into the hands of humanitarian aid and health workers: when they need it, where they need it.
MEDBOX is still under development! We are keen to receiving more documents, training materials and presentations relevant to improve the quality of health action! Your feedback is valuable to us, so do get in touch if you have something you'd like to share with us to improve on, and maximise, our collaborative space. Do send your comments to: info@medbox.org
MEDBOX. Capacity building and quality assurance through innovation.
For more information please go to our section of annual report here
The MEDBOX Team has started a new feature publishing Issue Briefs with different topics.
FILTER BY LANGUAGE
FILTER BY COUNTRY
RESULTS/PAGE
LIST TYPE
19 March 2021
временное руководство. Первый выпуск: 10 февраля 2021 г. Обновлено: 21 апреля 2021 г. Последнее обновление 30 июля 2021 ... more
orientations provisoires, première publication: 10 février 2021, mise à jour : 21 avril 2021, dernière mise à jour : 30 juillet 2021
Este documento de referência foi preparado pelo Grupo de Trabalho sobre Vacinas contra COVID-19 do Grupo Consultivo Estratégico de Especialistas em Imunização (SAGE) para orientar as discussões do SAGE em sua reunião extraordinária de 8 de fevereiro de 2021, que resultou na publicação do documento da OMS de 10 de fevereiro de 2021 Recomendações provisórias para o uso da vacina AZD1222 [ChAdOx1-S (recombinante)] contra COVID-19 desenvolvida pela Universidade de Oxford e pela AstraZeneca. Os dois documentos estão disponíveis na página sobre COVID-19 do SAGE: https://www.who.int/groups/strategic-advisory-group-of-experts-on-immunization/covid-19-materials. Têm sido usados vetores de adenovírus deficientes na replicação contendo um transgene específico do patógeno como novas vacinas devido à sua capacidade de induzir respostas humorais e celulares fortes ... more
Bisher hat die STIKO empfohlen, dass alle im Ausland mit einem nicht in der EU zugelassenen Impfstoff geimpften Personen eine erneute Impfserie mit einem in der EU zugelassenen Impfstoff erhalten sollen. Ziel der im Epidemiologischen Bulletin 13/2022 veröffentlichten aktualisierten COVID-19-Impfempfehlung ist es, Personen, die eine COVID-19-Impfung mit einem der nicht in der EU zugelassenen Ganzvirusimpfstoffen (CoronaVac, Covilo und Covaxin) oder dem Vektor-basierten Impfstoff Sputnik V erhalten haben, mit einem Impfschutz auszustatten, der vergleichbar mit dem einer Grundimmunisierung plus Auffrischimpfung mit einem mRNA-Impfstoff ist ... more
10 May 2021. Manufactureres: SK Bioscience Co. Ltd. [COVID-19 Vaccine (ChAdOx1-S [recombinant])] Serum Institute of India Pvt. Ltd. [COVISHIELD™, ChAdOx1 nCoV-19 Corona Virus Vaccine (Recombinant)] The ChAdOx1-S/nCoV-19 [recombinant] vaccine is a replication-deficient adenoviral vector vaccine against coronavirus disease 2019 (COVID-19). The vaccine expresses the SARS-CoV-2 spike protein gene, which instructs the host cells to produce the protein of the S-antigen unique to SARS-CoV-2, allowing the body to generate an immune response and to retain that information in memory immune cells. Efficacy shown in clinical trials in participants who received the full series of vaccine (2 doses) irrespective of interval between the doses was 63.1%, based on a median follow-up of 80 days, but tended to be higher when this interval was longer. The data reviewed at this time support the conclusion that the known and potential benefits of ChAdOx1-S/nCoV-19 [recombinant] vaccine outweigh the known and potential risks ... more
7 April 2021 Based on current information, a causal relationship between the vaccine and the occurrence of blood clots with low platelets is considered plausible but is not confirmed. Available in Englisch, French and Russia ... more
New England Journal of Medicine April 9, 2021 DOI: 10.1056/NEJMoa2104840
26 records
Showing 1 to 10 of 26 results
Add to my MEDBOX
View PDF
Download
